نتایج جستجو برای: imatinib mesylate

تعداد نتایج: 8770  

Journal: :Cancer research 2013
Sylvie Rusakiewicz Michaela Semeraro Matthieu Sarabi Mélanie Desbois Clara Locher Rosa Mendez Nadège Vimond Angel Concha Federico Garrido Nicolas Isambert Loic Chaigneau Valérie Le Brun-Ly Patrice Dubreuil Isabelle Cremer Anne Caignard Vichnou Poirier-Colame Kariman Chaba Caroline Flament Niels Halama Dirk Jäger Alexander Eggermont Sylvie Bonvalot Frédéric Commo Philippe Terrier Paule Opolon Jean-François Emile Jean-Michel Coindre Guido Kroemer Nathalie Chaput Axel Le Cesne Jean-Yves Blay Laurence Zitvogel

Cancer immunosurveillance relies on effector/memory tumor-infiltrating CD8(+) T cells with a T-helper cell 1 (TH1) profile. Evidence for a natural killer (NK) cell-based control of human malignancies is still largely missing. The KIT tyrosine kinase inhibitor imatinib mesylate markedly prolongs the survival of patients with gastrointestinal stromal tumors (GIST) by direct effects on tumor cells...

Journal: :Acta dermato-venereologica 2009
Tamihiro Kawakami Takeshi Kawanabe Yoshinao Soma

© 2009 The Authors. doi: 10.2340/00015555-0636 Journal Compilation © 2009 Acta Dermato-Venereologica. ISSN 0001-5555 Sir, Chronic myeloid leukaemia (CMV) is a clonal myeloproliferative disorder, in which the Philadelphia chromosome is the cytogenetic hallmark. It is characterized by the t(9;22) translocation, which in turn creates the chimeric bcr-abl oncogene coding for a constitutively activa...

Journal: :Blood 2006
Heather A Bradeen Christopher A Eide Thomas O'Hare Kara J Johnson Stephanie G Willis Francis Y Lee Brian J Druker Michael W Deininger

BMS-354825 (dasatinib) and AMN107 (nilotinib) are potent alternate Abl inhibitors with activity against many imatinib mesylate-resistant BCR-ABL kinase domain (KD) mutants, except T315I. We used N-ethyl-N-nitrosourea (ENU)-exposed Ba/F3-p210(BCR-ABL) cells to compare incidence and types of KD mutants emerging in the presence of imatinib mesylate, dasatinib, and nilotinib, alone and in dual comb...

Journal: :Indian Journal of Pharmaceutical Sciences 2022

In the present work high performance liquid chromatography method was developed and validated for imatinib mesylate its related substances. The analyzed active pharmaceutical ingredient impurities were separated by Atlantis T3 (150 mm×4.6 mm), 3 μm column with ultraviolet detection at 230 nm. mobile phase has been used in specific composition (50:50, v/v, organic inorganic) that prepared using ...

Journal: :Archives of dermatology 2009
Tracy Campbell Lesley Felsten Julie Moore

BACKGROUND Gastrointestinal stromal tumors (GISTs) harbor gain-of-function mutations of the c-kit tyrosine kinase receptor. Imatinib mesylate is an inhibitor of c-kit and is indicated in the treatment of chronic myeloid leukemia and GISTs. Reported adverse effects of imatinib include hypopigmentation, depigmentation, and hyperpigmentation. Although the exact mechanism by which these occur is un...

Journal: :FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2005
Shinong Wang Mark C Wilkes Edward B Leof Raimund Hirschberg

Transforming growth factor-beta (TGF-beta) is the single most important cytokine promoting renal fibrogenesis. p21-activated kinase-2 (PAK2) and activation of abelson nonreceptor tyrosine kinase (c-abl) have been shown recently to be smad-independent, fibroblast-specific targets downstream of the activated TGF-beta receptor. In the current study we show that in cultured NRK49F-renal fibroblasts...

Journal: :Asian Pacific journal of cancer prevention : APJCP 2011
M Ashraf J Jha A Choudhry B Aggarwal S Nayak J Chakraborty S Majumder J Biswas

BACKGROUND Imatinib mesylate is able to at least modify the course of gastrointestinal stromal tumours (GISTs). Neoadjuvant use for locally advanced lesions is evolving as a new treatment paradigm in this hitherto universally fatal disease. METHODS AND RESULTS The study patients with locally advanced GIST received neoadjuvant and adjuvant imatinib mesylate. Response was noted as per the RECIS...

Journal: :The Journal of the Association of Physicians of India 2007
V Talwar D C Doval Komal Bhatia

Sir, Imatinib mesylate is a tyrosine kinase inhibitor that targets BCR-ABL protein in chronic myelogenous leukemia (CML).1 We present three cases of CML, treated with Imatinib who developed clinical findings of hypopigmentation. All the three patients noticed pigmentation changes after the initiation of therapy with Imatinib mesylate, which was persistent during therapy. The presence of hypopig...

Journal: :Anticancer research 2007
Markos Ioannou Nikolaos Demertzis Ioanna Iakovidou Stamatios Kottakis

BACKGROUND Extra-abdominal desmoid tumors are rare neoplasms with variable biological behavior. The mainstay of treatment is surgery. Complementary treatment with tyrosine-kinase receptor inhibitor drugs, particularly imatinib mesylate, has been reported in the literature. The purpose of this study was to determine the possible presence of tyrosine-kinase receptors in extra-abdominal desmoid tu...

Journal: :Cancer research 2005
Magali Terme Christophe Borg François Guilhot Carole Masurier Caroline Flament Erwin F Wagner Sophie Caillat-Zucman Alain Bernheim Ali G Turhan Anne Caignard Laurence Zitvogel

BCR/ABL fusion gene, encoding a paradigmatic tyrosine kinase involved in chronic myelogenous leukemia (CML), can modulate the expression of genes involved in natural killer (NK) cell target recognition. Recent reports outline the role of allogeneic antileukemic NK effectors in the graft-versus-leukemia effect but the regulation of NK cell activation in the setting of graft-versus-leukemia effec...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید